Company intelligence / Profile preview

Medscint

Ownership: Private
Development stage: Commercial

Overview

Medscint develops and commercializes advanced plastic scintillation dosimetry systems—most notably the HYPERSCINT™ line—for accurate, real-time radiation dose measurements in modern radiotherapy. Their patented hyperspectral approach enables precise differentiation between scintillation and Cherenkov emissions, supporting challenging modalities such as ultra-high dose rate (FLASH) therapy. Their products are used by medical physicists and researchers globally to improve quality assurance in radiation oncology.

Therapeutic areas: Oncology
Modalities: Device (dosimetry)Scintillation dosimetry system (plastic scintillator-based)Radiotherapy quality control device
Industry: Therapeutic Medical Devices

Partnerships

Collaborates with academic institutions such as CERN CLEAR facility for VHEE studies; broader partnerships not specified but works closely with medical physicists/researchers worldwide.

Beyond the preview

Go deeper on Medscint.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medscint.

Explore the full profile